Item 2.02. Results of Operations and Financial Condition.

Applied Genetic Technologies Corporation (the "Company") is disclosing that its cash, cash equivalents and investments as of December 31, 2020 was approximately $53.1 million.

The foregoing information constitutes an unaudited and preliminary estimate that (i) represents the most current information available to management as of January 27, 2021, (ii) is subject to completion of financial closing and procedures that could result in significant changes to the estimated amount, and (iii) does not present all information necessary for an understanding of the Company's financial condition as of, and its results of operations for the fiscal quarter ended, December 31, 2020. Accordingly, undue reliance should not be placed on such estimates.

The information set forth in this Item 2.02 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or under the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.

Item 7.01. Regulation FD Disclosure.

On January 27, 2021, the Company issued a press release announcing updated information regarding its ongoing Achromatopsia (ACHM) clinical trials. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

The information set forth in this Item 7.01 and Exhibit 99.1 hereto are being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act or under the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.

Item 8.01. Other Events.

On January 27, 2021, the Company reported results in from its ACHMB3 and ACHMA3 clinical trials. For ACHMB3, the data consists of 12-month data from 15 patients, 9-month data from five patients, 6-month data from three patients and 3-month data from three patients for a total of 26 patients across all dose groups. These results reflect a further analysis of the data reported by the Company in November 2020 together with new data that became available in January 2021. Seven of the 16 patients in the three highest dose groups in the ACHMB3 trial showed improvements in visual sensitivity, in the treated area, as measured by static perimetry. No consistent results were seen in the other dose groups. In a subset of these patients with evaluable multi-focal electroretinograms (ERG), improvements in electrical signaling were measurable in the same treated area.

For ACHMA3, the new data analysis consists of 12-month data from 10 patients, 9-month data from four patients, 6-month data from one patient and 2 or 3-month data from three patients for a total of 18 patients across five dose groups. One additional patient did not have evaluable data. In the 16 patients in the four highest dose groups three patients showed improvements in visual sensitivity in the treated area as measured by static perimetry. No consistent results were seen in other dose groups. None of these three patients with improvements in visual sensitivity had evaluable ERGs.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits



Exhibit
  No.                                     Description

99.1           Press release issued by Applied Genetic Technologies Corporation on
             January 27, 2021 announcing updated information regarding its ongoing
             ACHM clinical trials




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses